Muddy waters: More stormy SEAS for ezetimibe

International Journal of Clinical Practice

Volumn 62, Issue 10, 2008, Pages 1470-1473

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

DISEASE COURSE; DRUG EFFECT; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

EID: 51349165703     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01888.x     Document Type: Review

References (39)

1. Nissen SE, Tuzcu EM, Brewer HB et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006 354 : 1253 63.
2. The Lipid Research Clinics (LRC) Coronary Primary Prevention Trial Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 251 : 351 64.
3. Jackevicius CA, Tu JV, Ross JS et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008 358 : 1819 28.
4. Altmann SW, Davis HR Jr., Zhu LJ et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004 303 : 1201 4.
5. Chang TY, Chang C. Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metab 2008 7 : 469 71.
6. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008 62 : 88 96.
7. Bays H, Rhyne J, Abby S et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006 22 : 2191 200.
8. Davis HR Jr., Pula KK, Alton KB et al. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001 50 : 1234 41.
9. Doherty E, Lumb PJ, Chik G et al. Ezetimibe-induced hyperlipidaemia. Int J Clin Pract 2005 Suppl. 147 : 3 5.
10. Wierzbicki AS, Doherty E, Lumb PJ et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005 21 : 333 8.
11. Miettinen TA, Kesaniemi YA. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989 49 : 629 35.
12. Gylling H, Miettinen TA. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis 2002 160 : 477 81.
13. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 358 : 1431 43.
14. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 2008 62 : 981 7.
15. Wierzbicki AS. A fishy business: omega-3 fatty acids and cardiovascular disease. Int J Clin Pract 2008 62 : 1142 6.
16. Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008 54 : 940 2.
17. Ford I, Murray H, Packard CJ et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007 357 : 1477 86.
18. Canner PL, Berge KG, Wenger NK et al. Fifteen years mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 8 : 1245 55.
19. Brown BG, Zambon A, Poulin D et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998 81 : 52B 9B.
20. Penning-van Beest FJ, Termorshuizen F, Goettsch WG et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007 28 : 154 9.
21. Rossebo AB, Pedersen TR, Allen C et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007 99 : 970 3.
22. Wierzbicki A, Shetty C. Aortic stenosis: an atherosclerotic disease? J Heart Valve Dis 1999 8 : 416 23.
23. O'Brien KD. Epidemiology and genetics of calcific aortic valve disease. J Investig Med 2007 55 : 284 91.
24. Graboys TB, Cohn PF. The prevalence of angina pectoris and abnormal coronary arteriograms in severe aortic valvular disease. Am Heart J 1977 93 : 683 6.
25. Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007 49 : 554 61.
26. Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005 352 : 2389 97.
27. Chan KL, Teo K, Tam J et al. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 2007 153 : 925 31.
28. Khumbani DJ. Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Cardiosource (American College of Cardiology). http://www.cardiosource.com/ clinicaltrials/trial.asp?trialID=1721 (accessed 22 July 2008).
29. Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart 2006 92 : 729 34.
30. O'Brien KD, Probstfield JL, Caulfield MT et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005 165 : 858 62.
31. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002 90 : 139 43.
32. Wierzbicki AS. Lipid lowering, statins and cancer. Int J Clin Pract 2006 60 : 1022 4.
33. Stein EA, Corsini A, Gimpelewicz CR et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract 2006 60 : 1028 34.
34. National Institute for Health and Clinical Excellence. Ezetimibe for the Treatment of Primary (Heterozygous-Familial and non-Familial) Hypercholesterolaemia: Technology Appraisal 132. London : Her Majesty's Stationery Office, 2007.
35. Charles Z, Pugh E, Barnett D. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance. Heart 2008 94 : 642 3.
36. Fichtlscherer S, Schmidt-Lucke C, Bojunga S et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006 27 : 1182 90.
37. Settergren M, Bohm F, Ryden L et al. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008 29 : 1753 60.
38. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 357 : 2001 15.
39. Wiviott SD, Cannon CP, Morrow DA et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005 46 : 1411 6.